Top 20 BioPharma Companies based on 2018 Total Revenue The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics […]readmore
Tags : Novartis
Shots: The P-III STR1VE study involves assessing of Zolgensma in 22 patients with SMA Type1 + one or two copies of the SMN2 backup gene + bi-allelic SMN1 gene deletion […]readmore
Shots: The BLA submission is based on P-III HAWK and HARRIER study results assessing brolucizumab (3/6 mg, q12w/q8w) vs aflibercept in 1800 patients with neovascular age-related macular degeneration nAMD or […]readmore
Shots: The approval is based on P-III CAIN457A2318 study results assessing Cosentyx (300/150 mg, q4w) vs PBO in 543 patients with moderate-to-severe plaque PsO. Additionally, P-III study in China assessed […]readmore
Shots: Novartis acquires IFM Tre, in all stock transaction for $1.575B. IFM Tre to receive $310M upfront & $1.265B milestones from Novartis. The transaction is expected to close in Q2’19 […]readmore
Shots: The approval is based on P-III EXPAND study results assessing Mayzent vs PBO in 1,651 patients with SPMS from 31 countries aged 48yrs. P-III study results: reduction in risk […]readmore
Shots: Novartis plans spin-off of its eye care business with an expected 100% spin-off on Apr 9, 2019 and has secured debt financing of $3.5B through banks Novartis stockholder to […]readmore
Shots: The PIONEER-HF 4-week extension study involves assessing Entresto vs Enalapril in ~832 patients with systolic heart failure treated with Entresto for the first 8 wks.& the last 4wks and […]readmore
Shots: Secure Bio to get WW commercialization rights for Farydak (panobinostat) from Novartis to treat patients with r/r multiple myeloma with no prior treatment The focus of the acquisition is […]readmore
Shots: The P-III study involves assessing Cosentyx (secukinumab, 150mg & 300mg) in 543 patients with moderate to severe plaque psoriasis in China The P-III study results: PASI 75 & PASI […]readmore